-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on July 20, the medical sector was acti.
In terms of individual stocks, Pumen Technology rose by more than 12%, Aoyuan Meigu, Chuangxin Medical, Ogilvy Medical, Langzi Shares, Harbin Sanlian and other stocks At the daily limit, Bloomage Bio, Amic and others followed su.
CITIC Securities stated in the research report that in the first half of the year, especially in the second quarter, the beauty track was more stable and less impacted than other options, and the industry's marginal recovery in June was significant; the overall medical beauty track Against the trend of positive growth, the proportion of light medical beauty has increased rapid.
Looking forward to the second half of the year, beauty cosmetics and medical beauty have entered the peak consumption season, and are still expected to be the areas with the highest growth rate in optional consumpti.
Among them, the medical beauty market is in a stage of positive growth against the tre.
According to Frost & Sullivan data, the scale of China's medical beauty market in 2021 will be 181 billion yuan, a year-on-year increase of 21%; the above-mentioned institutions predict that it will reach 632 billion yuan in 2030, corresponding to 2021-2026E CAGR increased by 12%, of which surgical/non-surgical CAGR increased by 11%/14%, corresponding to a 14% increase in 2026E-2030E CAGR, of which surgical/non-surgical CAGR increased by 2%/10% respective.
It is worth mentioning that although the medical aesthetics market has a broad space, the relevant departments have also strengthened the market consolidation of the medical aesthetics industry in recent yea.
For example, in 2021, the eight departments jointly issued a document, deciding to jointly carry out the special rectification work against illegal medical and cosmetic services from June to December 2021, and issued the "Special Rectification Work Plan for Combating Illegal Medical and Cosmetic Service.
Normative development will play a ro.
The agency believes that there is still a lot of room for improvement in the penetration rate of medical beauty, and with the strengthening of supervision, the compliant market is expected to form an accelerated replacement for the non-compliant mark.
In terms of individual stocks, I am optimistic about Amic, Bloomage Bio, and Haohai Biotechnolo.
Amic is a leading non-surgical medical beauty compa.
The company started out in the hyaluronic acid business and occupies a dominant position in the domestic sodium hyaluronate medical beauty preparation fie.
After landing on the GEM of the Shenzhen Stock Exchange in 2020, the company's stock price has skyrocketed, and its market value has soared to 280 billion yu.
The company's gross profit margin has exceeded 90% in the past three yea.
In the field of medical beauty, the company has comprehensively deployed medical beauty terminal products, and its revenue and net profit have also ris.
In 2021, Aimeike's revenue will be 448 billion yuan, a year-on-year increase of 101
Net profit was 957 million yuan, a year-on-year increase of 128
Bloomage Bio is a supplier of the whole industry chain with hyaluronic acid as the co.
The company has upgraded from a hyaluronic acid raw material manufacturer to a new four-wheel drive development model of bioactive raw materials, medical terminals, functional skin care products and functional foo.
Incubation of new products and diversified business strategies were carried out in parallel, and revenue maintained rapid and steady grow.
The 2021 financial report shows that the company's annual operating income was 948 billion yuan, a year-on-year increase of 893%; the net profit attributable to shareholders of the listed company was 782 million yuan, a year-on-year increase of 21
Haohai Biotechnology is an international medical device platform enterprise driven by ophthalmology and medical cosmetolo.
The company started with biomedical material technology and genetic engineering technolo.
In the four major sections of adhesion and hemostasis, its self-developed domestic first single-phase cross-linked hyaluronic acid product "Haiwei" was successfully launched in 2013, opening a chapter in the company's medical beauty developme.
According to the introduction of Haohai Biotechnology, the company has formed a product portfolio layout of "hyaluronic acid + botulinum toxin + optoelectronic equipment" in the field of medical beauty, covering three major application scenarios of medical beauty, life beauty and home beau.
The financial report shows that the company will achieve revenue of 767 billion yuan in 2021, a year-on-year increase of 361%; net profit attributable to the parent is 352 million yuan, a year-on-year increase of 5
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In terms of individual stocks, Pumen Technology rose by more than 12%, Aoyuan Meigu, Chuangxin Medical, Ogilvy Medical, Langzi Shares, Harbin Sanlian and other stocks At the daily limit, Bloomage Bio, Amic and others followed su.
CITIC Securities stated in the research report that in the first half of the year, especially in the second quarter, the beauty track was more stable and less impacted than other options, and the industry's marginal recovery in June was significant; the overall medical beauty track Against the trend of positive growth, the proportion of light medical beauty has increased rapid.
Looking forward to the second half of the year, beauty cosmetics and medical beauty have entered the peak consumption season, and are still expected to be the areas with the highest growth rate in optional consumpti.
Among them, the medical beauty market is in a stage of positive growth against the tre.
According to Frost & Sullivan data, the scale of China's medical beauty market in 2021 will be 181 billion yuan, a year-on-year increase of 21%; the above-mentioned institutions predict that it will reach 632 billion yuan in 2030, corresponding to 2021-2026E CAGR increased by 12%, of which surgical/non-surgical CAGR increased by 11%/14%, corresponding to a 14% increase in 2026E-2030E CAGR, of which surgical/non-surgical CAGR increased by 2%/10% respective.
It is worth mentioning that although the medical aesthetics market has a broad space, the relevant departments have also strengthened the market consolidation of the medical aesthetics industry in recent yea.
For example, in 2021, the eight departments jointly issued a document, deciding to jointly carry out the special rectification work against illegal medical and cosmetic services from June to December 2021, and issued the "Special Rectification Work Plan for Combating Illegal Medical and Cosmetic Service.
Normative development will play a ro.
The agency believes that there is still a lot of room for improvement in the penetration rate of medical beauty, and with the strengthening of supervision, the compliant market is expected to form an accelerated replacement for the non-compliant mark.
In terms of individual stocks, I am optimistic about Amic, Bloomage Bio, and Haohai Biotechnolo.
Amic is a leading non-surgical medical beauty compa.
The company started out in the hyaluronic acid business and occupies a dominant position in the domestic sodium hyaluronate medical beauty preparation fie.
After landing on the GEM of the Shenzhen Stock Exchange in 2020, the company's stock price has skyrocketed, and its market value has soared to 280 billion yu.
The company's gross profit margin has exceeded 90% in the past three yea.
In the field of medical beauty, the company has comprehensively deployed medical beauty terminal products, and its revenue and net profit have also ris.
In 2021, Aimeike's revenue will be 448 billion yuan, a year-on-year increase of 101
Net profit was 957 million yuan, a year-on-year increase of 128
Bloomage Bio is a supplier of the whole industry chain with hyaluronic acid as the co.
The company has upgraded from a hyaluronic acid raw material manufacturer to a new four-wheel drive development model of bioactive raw materials, medical terminals, functional skin care products and functional foo.
Incubation of new products and diversified business strategies were carried out in parallel, and revenue maintained rapid and steady grow.
The 2021 financial report shows that the company's annual operating income was 948 billion yuan, a year-on-year increase of 893%; the net profit attributable to shareholders of the listed company was 782 million yuan, a year-on-year increase of 21
Haohai Biotechnology is an international medical device platform enterprise driven by ophthalmology and medical cosmetolo.
The company started with biomedical material technology and genetic engineering technolo.
In the four major sections of adhesion and hemostasis, its self-developed domestic first single-phase cross-linked hyaluronic acid product "Haiwei" was successfully launched in 2013, opening a chapter in the company's medical beauty developme.
According to the introduction of Haohai Biotechnology, the company has formed a product portfolio layout of "hyaluronic acid + botulinum toxin + optoelectronic equipment" in the field of medical beauty, covering three major application scenarios of medical beauty, life beauty and home beau.
The financial report shows that the company will achieve revenue of 767 billion yuan in 2021, a year-on-year increase of 361%; net profit attributable to the parent is 352 million yuan, a year-on-year increase of 5
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
